(Total Views: 130)
Posted On: 05/05/2017 2:49:28 PM
Post# of 2218
$NEOS / Neos Therapeutics (NASDAQ: NEOS) which is up some 25% since it was first recommended in these pages in late January but even further upside seems likely given its current momentum.
This $150 million market cap company is largely targeting the ADHD space which is roughly a $9 billion annual market. Its first product on the market is a compound called Adzenys. This once-a-day FDA-approved product was launched in the second quarter of last year and is seeing impressive script growth in the initial phase of its launch.
Another product called Cotempla should be approved in early summer and be on the market before the end of this year. With this launch, the company will have complete coverage of the stimulant part of ADHD space. The company also sells generic Tussionex (a cough suppressant) that does around $6 million of annual revenues.
While not yet profitable, the company should see explosive growth in coming years. Even a two percent share of the ADHD market would make the stock extremely cheap at current levels.
This $150 million market cap company is largely targeting the ADHD space which is roughly a $9 billion annual market. Its first product on the market is a compound called Adzenys. This once-a-day FDA-approved product was launched in the second quarter of last year and is seeing impressive script growth in the initial phase of its launch.
Another product called Cotempla should be approved in early summer and be on the market before the end of this year. With this launch, the company will have complete coverage of the stimulant part of ADHD space. The company also sells generic Tussionex (a cough suppressant) that does around $6 million of annual revenues.
While not yet profitable, the company should see explosive growth in coming years. Even a two percent share of the ADHD market would make the stock extremely cheap at current levels.
(0)
(0)Scroll down for more posts ▼
